Hey GF, Nice call on the DOW.
Close enough to be spot on for sure.

you posted this on Monday May 10th-
"I expect the Dow to tip above the 11000 area maybe once more than work its way back to the low of the spike down from the big scare last week. I assure you the spike is a guide and set point."

And sure enough May 13th the DOW rose to 10920.27, then fell to 9918.82 low (near the May 6th flash crash low of 9869.62) this past Friday May 23rd.

Have a great week- d

CCME: HEy bUrRpPPP,

I'm sure you've seen this, good news for CCME.

China MediaExpress Holdings, Inc. to Begin Trading on the NASDAQ Global Select Market on June 3rd

Effective as of the close of trading on June 2, 2010, the Company's common stock will cease trading on NYSE AMEX. Upon the opening of trading on June 3, 2010, the Company's shares will commence trading on NASDAQ Global Select Market, under the same ticker symbol "CCME".

Also, I was at Burp Castle this past Saturday night having some beers. It's funny how they're always shushing everybody to be quiet in keeping with the monk/monastery motif.

later- d

RDN- Hey eelfland,

Your post definitely caught my eye.
I have been watching and playing RDN off and on since the middle of March.

So IMHO, I would say at first glance that next strong support is presently 8.95 at the 200MA.
RSI 14 has just breached below 30 into oversold territory, and low's StochRSI 14 is well into oversold territory.

Fundamentally, RDN just recently reported a Q1 loss/share of $3.77 vs $2.69 yr-ago and today had a stock offering of 50M shares at $11/shr, so I'm interested to see how that affects the PPS going forward from here, as well as the overall market right now.
But also today AH, RDN's outlook was raised from negative to positive.

I threw an annotated chart together quickly also pointing out overhead Gaps that could fill on an upside bounce. (Not my best chart, just a quick one)


I will definitely be keeping an eye on this one and I look forward to hearing your thoughts as well.

thanks -D

That's good to know.
Thanks for the info GF.
-d

SDS good today too for down market

and surprisingly MSPD

I've been watching the L2 on POZN the past couple of days and it seems that whomever is using the ECN- ISEG, is doing the shorting right now.
Saw what seemed like them covering two 25k lots yesterday (huge buy volume but no price movement), it was wild to watch, I'm not an L2 expert, but that's what it looked like

and today they're back in the axe position
approval day will be interesting to say the least

-d

SRZ- Thanks lowtrade, as always, for your observation.

I should have prefaced my post with 'Early Heads Up'
or something like that.I will make sure I'm more concise in the future, I would hate to misinform anyone on the board.

Yes, totally agree with indicators not set up quite yet and the longer time frame it took to form the Cup & Handle. nice reminder on possible retail mindset.

I have it on watch for resistance break as well, but did you mean you have a buy stop at $5.80 and not $6.80?
like you said, could have played the handle for the pivot point reversal, it did bounce nicely off of the 5.08 support area.

I will be watching for volume as well.

(I also put a 20SMA overlay on the indicators, just for fun put one over the StochRSI(14) and watch where the StochRSI crosses up through the 20MA overlay, esp over the past 7 months or so on the SRZ Daily chart, pretty interesting...I mention that now because the StochRSI is now crossing above the 20MA overlay again. Seems to have some pretty decent moves after this happens. Just a pattern I've noticed that I wanted to share with you.)

Thanks again- d

SRZ Cup w/ Handle beginning to move

see my previous post with chart
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=48396308

and see lowtrade's reply to my post for his extra notes

Hey lowtrade,

I just wanted to get your opinion on this SRZ Cup with Handle annotation I did here and see that I'm in the right ballpark.
I forgot to turn off the Bollies for this one, so it's a little busier than usual.
And I'm really enjoying your video posts. Looking forward to the next one.

thanks man
-D

"AENY moved off the two day reversal
This was a classic move"

Damn right it did.
I saw that.
You Rock Ken.

-D

Hey GF
hope you're well.
Was thinking that too and been using your 15 min indicator technique during those times after you posted about it a while back.
check out RDN for possible eventual swing bounce?
15min- RSI's, Willy, +D and 20MA overlays are bottomed out after today's sell off.

later- D

Hey lowtrade,

just finished watching your FLWS video.
Thanks for making it.
It also refreshed my take on the indicators.
I'm still keeping an eye on that SAR technique of yours too. ;)

later -d

Thanks for confirming the H&S on PLD and explaining more about the neckline for me lowtrade.

And since it's in play and looks good for another 9-10%, check it out longer term also, as another 9-10% gain will take it above it's 54 week high and after that, resistance seems negligible.
Also the SAR on the weekly just flipped under.
May be good for more beyond the H&S pattern target.
We'll see.

Thanks again.
-d

Hi lowtrade. PLD H&S Bottom question.

I'm not sure if I'm correctly identifying the neckline in this H&S bottom reversal pattern.
I tried picking it out as best I could for the moment and would appreciate your input.
thanks! -d

Hey burp,

I haven't posted here much, but always appreciate your posts and enjoy reading them.
just curious what an s-3 is that you're referring to with your post on TSTC in relation to shorts?

thanks -d

that is a bad a$$ pic of Angus

Hey spectrader,

That chart has the log scale selected.
lowtrade mentioned how the log scale will distort charts, that without it, they're more accurate, and IMO they are, so I turn it off.

In the end, charting is a matter of preference I guess, as I'm sure you know, so to each his own, but here's NEXM with the log scale turned off and like you said you cannot annotate it the way the other chart was done.

Without the log scale turned on it looks more like a Bullish flag pattern with a possible target of .89, depending on where it breaks out around .55 or below.
JMHO

later- d

http://stockcharts.com/h-sc/ui?s=NEXM&p=D&yr=0&mn=6&dy=0&id=p25516390036

Nice play for sure then on JTX. Both ways.
That's the way to do it.
And I'm good thanks for asking.
I'm still working on my flow, aren't we all.

IMO, If ACLS is an H&S pattern (starting from first week in JAN) then the neckline is at $1.50 where the 50DMA is also.
Could also be a triple top, as $1.80 seems to be the average defining resistance area (the ole' candle bodies vs shadows debate right?).
Either way they're both reversal patterns of an upwards trend and ACLS has been trending up since the beginning of NOV.
hmmmmm...

Looking forward to an interesting week.
Futures looking green and good for tomorrow.

later- d

Hey stockauthorata
Nice call on the JTX no mas
bounced back right off that $2.93ish resistance

"this DOW needs an enema!"
(in the voice of Jack Nicholson as the Joker)
especially a Krakatoa enema. LOL.

hey valuemunger,

good to hear from you.
GLTU during this wacky chit.

-d

Gangreen on the Dow again today huh Ken?

oops sorry wrong reply
please delete

Good Morning Chartinator.

I didn't notice the Phoenix Rising for BSPM also.
thanks for pointing that out, very cool.

thanks- d

Hey Chartinator,

Would you say that BSPM has what looks like a
confirmed Magic Box with a forward looking
Krakatoa in the making?

thanks.
later- d

Right on, thanks for pointing that out Chartinator.

Have a great week.

-d

Sounds cool Chartinator, I'll be keeping an eye on these tomorrow.

Also, I did a quick scan on stockcharts and COOL came up with a Bullish Engulfing candle.
And the Weekly chart looks like a possible pivot point reversal.

later- d

Hey plastipunk,

Chartinator mentioned watching KMKCF on the WU site, because of the Bullish Engulfing candle on Fri. and with it being in Gold Rush too, looks like it's worth watching short term and long term.

the 2MA seems to be in a good spot in and right above the center of the candle and turning up.

later- d

Nice picks xela as always.
I like DPTR.
have had an eye on it for a few days.
It's now creeping into Krakatoa land.

Also has an ascending triangle pattern (which I think is still valid, market tried to bring it under the trendline but it bounced back nice enough) with a break above $1.45-50 and a target of $2.12, with a Gap to fill (can see it on 6mo chart) from $2.65-$4.00.



-d

Hey lowtrade,
Hope everything's great on your end.

I have another chart I'd like for you to please give a critique on, very possible ascending pattern play here with DPTR.
I'm still trying to spot them more successfully.
this one jumped out at me in particular.

thanks- d

Orion Party Bash MLK Day Contest Pick - PFSW (3.78)

CCME Wow.

great bullish confirmation with volume and that long white candle after the inverted hammer candle.

And Skywalking!

GLTA- d

Hey $heff,

Great board here and very much appreciated.

I'm curious as to your take on the recent Street.com article concerning ANX.
thanks-d

http://www.thestreet.com/story/10661651/1/biotech-stock-mailbag-adventrx-pharmaceuticals.html

"I attended the Adventrx presentation in San Francisco on Wednesday and spent some time afterward with CEO Brian Culley. Adventrx is a feel-good comeback story in that the company was essentially on life support (and probably should have went under) in 2007 after the failure of its "Co Factor" chemotherapy drug.

Culley deserves credit for somehow managing to keep Adventrx alive. His perseverance paid off last month when the company was able to seek regulatory approval in the U.S. for its first drug candidate, a reformulation of the chemotherapy drug navelbine, known generically as vinorelbine. Adventrx also raised money last week, and with $20 million in total, now has some much-needed breathing room.

Unfortunately, the years Adventrx spent in the wilderness are going to make it difficult for its reformulated chemotherapy drugs to gain traction commercially. These are niche drugs and Adventrx is going to have a tough time making any money selling them.

I know Adventrx looks cheap (share priced around 40 cents cents, a $60 million market cap), but as I'll explain below, I think the company's operating business has some real challenges.

ANX-530 is the name of Adventrx's reformulated vinorelbine currently under FDA review. ANX-530 appears to be bioequivalent to vinorelbine, based on the pharmacokinetic data that formed the basis of the FDA filing. Moreover, Adventrx says ANX-530 causes less vein irritation than vinorelbine when administered to patients.

I have no beef with any of these Adventrx claims. The problem, however, is that ANX-530, if approved in the U.S., is entering a very small commercial market in non-small cell lung cancer where it will have to compete against generic (read: inexpensive) vinrorelbine.

Adventrix chief Culley says the addressable commercial market opportunity for ANX-530 in non-small cell lung cancer is $200 million in the U.S. - but that's a made up number and wildly unrealistic.

Total vinorelbine sales in the U.S. are about $20 million annually, according to research firm IMS Health. That's the real addressable market opportunity for ANX-530.

Culley comes up with $200 million because he commissioned some market research that concluded that doctors would be willing to use ANX-530 over vinorelbine even at ten times the generic price. (Adventrx paid for the market research, so results aren't exactly unbiased.)

In other words, if ANX-530 totally replaced generic vinorelbine in the U.S. and ANX-530 was priced at ten times (!!!) the generic vinorelbine price, Adventrix could generate $200 million in ANX-530 sales.

Sorry, but a conclusion like that strains credibility.

In the real world, doctors in the U.S. do not use very much vinorelbine to treat non-small cell lung cancer patients, which is why sales are so low. The preferred chemotherapy regimen here is a combination of carboplatin and paclitaxel. (Vinorelbine is used more in Europe.)

Vinorelbine is very cheap and vein irritation occurs in only about 30% of patients, so it's not a huge problem. ANX-530 is simply not differentiated enough for doctors to switch, especially since ANX-530 will cost more. (Perhaps a lot more if Culley prices the drug based on his market research.)

Adventrx also has problems with its second pipeline drug, a reformulation of the chemotherapy drug docetaxel known as ANX-514.

Docetaxel, sold under the brand name Taxotere by Sanofi-Aventis, is a $3 billion-dollar chemotherapy drug, so Adventrx is targeting a very lucrative commercial market.

Unfortunately, Adventrx has not established crystal-clear bioequivalence between ANX-514 and docetaxel based on the results from the company's small pharmacokinetic study. Culley concedes that he can't file for approval based on the data he has so far. The company is going to meet with the FDA to establish next steps, which may involve more clinical trials. (Culley is hoping that this isn't necessary but he certainly can't guarantee it.)

The other problem for ANX-514 is that there are no data conclusively showing any favorable benefit -- safety, efficacy or tolerability -- over docetexal. Culley says that doctors might infer that ANX-514, which lacks the detergents contained in docetaxel, causes less hypersensitivity reactions in patients, but he says the company has no conclusive data to make that claim.

And let's not forget that the branded patent life on docetaxel is rapidly coming to a close. Cheap, generic docetaxel could hit the market as early as this spring, if generic drugmakers win court challenges. If not, generic docetaxel will definitely hit the market in 2013. Adventrx is simply running out of time.

One last thing: Yes, billionaire investor Carl Icahn does own a considerable stake in Adventrx, but it's important to understand that Icahn bought his position years ago before CoFactor failed (and at a much higher price.) Icahn's biotech lieutenant Alex Denner used to sit on Adventrx's board, but no longer.

"I recognize the buzz that comes from Icahn owning our stock, but it's a passive position," Culley says."

Thanks for the welcome langlui, and thanks for that reminder, yes, the ole' $1 mental resistance level...
I'll remember to add that if need be, in the future.
Still working out the kinks when trying to verbalize a chart setup.

And yes my alias is a bit longish. LOL.
Impulse pick I suppose.
which is why I just sign off with...-d

(even I don't want to type the whole thing.)

Great day tomorrow to everyone here.

-d

Great board here Langlui!

-d

maskone-

I saw your post and thought I'd oblige with a chart for TSFG.

Looks like it needs a little more time to cook since most of the indicators are trending down, but it's been basing for a little while and the PPS has closed above the 50dma for 5 days now and other MA's seem to be slowly turning up.
Resistance at .75,.85 and a GAP to fill from $1.10-$1.42
but now as I'm typing I see it's up in AH on news, and news trumps all:
http://finance.yahoo.com/news/Carolina-First-Bank-Approved-bw-3400168803.html?x=0

I'm still trying to get the swing of this and haven't figured out how to post an annotated chart that updates yet and is not just static, so I would be interested to hear what else you saw in the chart that looks like a buy, you may have other indicators than I use.

Thanks-
d

With Krakatoa, Skywalk, Bull Raid etc. and their awesomeness, I can't wait to find out what the Black Beauty setup is someday.

-d

Hey Chartinator.

I was wondering where you get the "Weekly Stock Movers By Sector" graph from (like the one you posted in Post#122957) and where I might find it?

After reading more of the Stan Weinstein book I realized I should incorporate more of a larger market and sector overview into my trading plans.

Take it Easy
-d

Thanks lowtrade!

Yeah I saw the 50dma cross below the 200dma on ARNA, but forgot to call it out, Huge technical move not to draw attention to, thanks for pointing that out.
Would that be a Reverse Golden Cross? Or some opposite of Gold, so maybe a Lead Cross? LOL.

I also forgot to draw the zig-zag lines in the ascending triangle, I'll have to remember that next time.

And thanks for clarifying support/ resistance when playing a pattern vs. having no pattern present.

And I quote: "Without a pattern to be relayed on, this main support/resistance point normally holds, and is pretty good until a chart pattern shows up to challenge it."

Which makes more sense and seems obvious to me now after you explained it, since now I realize that first, it takes testing the support and resistance levels more than once to begin creating a pattern and then qualifying it with 2 or more (preferably 3) touches for a possible breakout signal, with news trumping all.

Have a great day
-d

And so was PAL.

Man, ever since it Pre-Skywalked on DEc 24th to Skywalking on Dec 28th, it's been in an almost perfect 45 degree angle uptrend ever since.
Just beautiful.
Skywalking is the perfect name for that setup.

Ken, your midachlorian count must be off the charts. LOL.

-d